Personalized and genetically engineered animal models for next-generation surgical implant validation

The creation of personalized and GEAMs has revolutionized preclinical validation of next-generation surgical devices due to the increased physiological and predictive relevance. The present review outlines the qualitative and quantitative evaluations of implant performance in bespoke animal models and focuses on bone, cardiovascular, neural, and soft tissue implants. The CRISPR/Cas9 and transgenic techniques allow transgenic modifications in donor PSCs to generate humanized immune responses, better disease modeling, and in situ biomimicry to develop tissue-organotropism. The biomechanically Engineered Genetic Model (EGM) scaffolds promote bone development under quantification from the osteoporotic rat models, whereby decreasing RUNX2 by over 45% in the early season of post-implantation. Similarly, humanized porcine models for cardiac implants exhibit a 30% increase in the rate of endothelialization, decreasing thrombosis risk. Immune-humanized mouse models show that qualitative evaluations suggest improved integration and longevity of the implant and decreased rejection, inflammatory responses, and formation of fibrous capsules. For example, smart implants equipped with biosensors and drug-delivery systems in genetically modified diabetic rodent models achieve 60% faster wound healing, showcasing the potential of combined strategies between bioengineered implants and disease-specific animal models. DiStAff (Disease-Specific Animal Models for Affinity-Based Functional Frameworks) experimental or clinical challenges include genetic drift, ethical considerations and translational gaps. The review highlights preclinical progress, regulatory considerations, and future blueprints to ensure personalized implant technology is in line with its clinical effectiveness and patient-specific requirements.